A, W., EM, B., D, C., GD, C., JP, S., LE, S., . . . F, S. (2024). Long-term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3-year results from the cannabidiol expanded access program. Epilepsia open, 9(5), 1816. https://doi.org/10.1002/epi4.13013
Chicago Style (17th ed.) CitationA, Weinstock, Bebin EM, Checketts D, Clark GD, Szaflarski JP, Seltzer LE, Thiele EA, and Sahebkar F. "Long-term Efficacy and Safety of Cannabidiol in Patients with Tuberous Sclerosis Complex: 3-year Results from the Cannabidiol Expanded Access Program." Epilepsia Open 9, no. 5 (2024): 1816. https://doi.org/10.1002/epi4.13013.
MLA (9th ed.) CitationA, Weinstock, et al. "Long-term Efficacy and Safety of Cannabidiol in Patients with Tuberous Sclerosis Complex: 3-year Results from the Cannabidiol Expanded Access Program." Epilepsia Open, vol. 9, no. 5, 2024, p. 1816, https://doi.org/10.1002/epi4.13013.
